No documentation related to hard outcomes, such as macrovascular or microvascular complications, were needed to gain FDA approval for marketing in the U.S., despite the known 2- to 4-fold greater risk for experiencing CV events in individuals living with diabetes
Fake doctor endorsements attempt to establish false legitimacy
Unlike Ozempic, which works through GLP-1 alone, retatrutide adds GIP and glucagon receptor activity on top of the GLP-1 backbone
Can retatrutide replace diet and exercise
there is also data to suggest that slower titration regimens (employed in GLP-1-insulin combo therapies), may reduce rates of nausea and vomiting further
Quando administrada por injeo subcutnea, a semaglutida estimula a secreo de insulina, inibe o glucagon, retarda o esvaziamento gstrico e promove a saciedade, resultando na reduo dos nveis de glicose no sangue e na perda de peso em pacientes com DM2 e obesidade (BAGGIO